www.amgenmedinfo.com
866-572-6436
DISEASE EDUCATION:
Underlined terms can be clicked for definition.
Neuroendocrine prostate cancer (NEPC) is an aggressive type of cancer that develops in the prostate gland, typically in patients previously treated with hormonal therapy.
Though NEPC can be the initial cancer diagnosis for some, it usually occurs in patients with metastatic castrate-resistant prostate cancer (mCRPC) when the cancer cells transform and no longer respond to therapy. In this situation, the cancer is often called treatment-emergent NEPC.
The number of patients with NEPC is increasing. Some studies suggest that as many as 1 in 5 men with mCRPC will show signs of NEPC transformation in their tumor1.
To determine if you may be eligible for a clinical study for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.
NEPC is an aggressive type of cancer that develops in the prostate gland. Diagnosis of NEPC is usually based on a biopsy of the cancer. Biopsies are often performed in metastatic castrate-resistant prostate cancer (mCRPC) patients with particularly aggressive disease and/or disease progression with low or non-rising PSA levels.
NEPC can sometimes be diagnosed from a blood sample by looking for genetic changes in the DNA from the cancer2.
It is important to speak with your doctor and ask if further testing may be needed.
For patients with NEPC, clinical studies may be an option.
1Aggarwal R, et al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. Journal of Clinical Oncology 36: 2492-2503, 2018.
2Beltran H, et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. Journal of Clinical Investigation 130(4): 1653-1668, 2020.
What is the
DeLLpro-300 study?
DeLLpro-300 is a clinical study that is testing an investigational drug called tarlatamab. The study is being done to see how safe and effective tarlatamab is at treating patients with neuroendocrine prostate cancer (NEPC) that has spread to another site in the body after one previous treatment.
If you are a physician or another healthcare professional interested in learning more about a tarlatamab clinical study or referring a patient, please contact an Amgen Medical Information Healthcare Professional.
Where can I get more information?
To determine if you may be eligible for a clinical study for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.